Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

for the, JCOG0605 investigators

Research output: Contribution to journalArticlepeer-review

77 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences